Insilico Medicine Featured in Harvard Business School Case Study on Rentosertib

The page describes a 2023 licensing deal between Insilico Medicine and Exelixis for ISM3091, described as a potentially best-in-class USP1 inhibitor for BRCA-mutated tumors. The deal is stated as $80 million upfront plus up to $900 million in additional milestone payments.

Insilico Medicine is an AI-native biotech running its own generative-chemistry drug-discovery platform (Pharma.AI), and licensing it through partnerships with major pharma companies.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.